NeraCare Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Private

  • Employees
  • 9

Employees

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $21.6M

  • Investors
  • 4

NeraCare General Information

Description

Developer of a diagnostic multi-gene expression test designed to predict the course of skin cancer disease. The company offers a qRT PCR genevexpression test for stage risk assessment and a seven protein immunohistochemistry assay for identifying high risk early stage patients, supported by multi study clinical validation and a randomized trial program, with recent licensing to a spatial imaging platform for scaled development and deployment, enabling oncologists and trial sponsors to select appropriate candidates, refine follow up, and inform treatment planning.

Contact Information

Website
neracare.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Maximilianstrasse 35a, Eingang A
  • 80539 Munich
  • Germany
+49 089
Primary Industry
Biotechnology
Other Industries
Diagnostic Equipment
Vertical(s)
HealthTech, Life Sciences, Oncology
Corporate Office
  • Maximilianstrasse 35a, Eingang A
  • 80539 Munich
  • Germany
+49 089

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

NeraCare Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Later Stage VC (Series A) 23-May-2024 $21.6M Completed Clinical Trials - Phase 3
1. Accelerator/Incubator Completed Startup
To view NeraCare’s complete valuation and funding history, request access »

NeraCare Patents

  • 8

    Total Documents Applications and Grants

  • Total Patents Families

  • 3

    Granted

  • 3

    Pending

  • Expiring in next 12 mo

NeraCare Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2025233414-A1 Companion diagnostic for early-stage melanoma Pending 06-Mar-2024
WO-2025186331-A1 Companion diagnostic for early-stage melanoma Pending 06-Mar-2024
WO-2025186331-A8 Companion diagnostic for early-stage melanoma Pending 06-Mar-2024
EP-4443315-A1 Technique for obtaining a prognostic risk score based on a histological image of a stained tissue sample of a patient having a melanoma Inactive 06-Apr-2023
AU-2009349220-A1 Methods of predicting clinical outcome in malignant melanoma Active 29-Jun-2009 G01N33/5751
To view NeraCare’s complete patent history, request access »

NeraCare Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

NeraCare Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
Bayerische Beteiligungsgesellschaft Venture Capital Minority
MIG AG Venture Capital Minority
Synvie Corporation Minority
German Accelerator Accelerator/Incubator
To view NeraCare’s complete investors history, request access »

NeraCare Acquisitions (1)

NeraCare’s most recent deal was a Merger/Acquisition with Synvie. The deal was made on 06-Mar-2020.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Synvie 06-Mar-2020 Merger/Acquisition Media and Information Services (B2B)
To view NeraCare’s complete acquisitions history, request access »

Ready to get started?

Request a free trial

NeraCare Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
Synvie Munich, Germany 2013

NeraCare FAQs

  • When was NeraCare founded?

    NeraCare was founded in 2015.

  • Where is NeraCare headquartered?

    NeraCare is headquartered in Munich, Germany.

  • What is the size of NeraCare?

    NeraCare has 9 total employees.

  • What industry is NeraCare in?

    NeraCare’s primary industry is Biotechnology.

  • Is NeraCare a private or public company?

    NeraCare is a Private company.

  • What is the current valuation of NeraCare?

    The current valuation of NeraCare is .

  • What is NeraCare’s current revenue?

    The current revenue for NeraCare is .

  • How much funding has NeraCare raised over time?

    NeraCare has raised $21.6M.

  • Who are NeraCare’s investors?

    Bayerische Beteiligungsgesellschaft, MIG AG, Synvie, and German Accelerator have invested in NeraCare.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process